Search Results for: US Stem Cell

3rd Invitrx warning highlights FDA oversight weakness

The FDA seems oddly slow in oversight of unproven stem cell clinic-related firms like one here in California called Invitrx Therapeutics. I’ve written before about Invitrx, but interactions between them and the FDA have continued including a new warning letter. It’s become a puzzling situation. More broadly, the FDA has done relatively little in the past […]

3rd Invitrx warning highlights FDA oversight weakness Read More »

2nd chances after big misconduct? He Jiankui, James Wilson, others

James Wilson, Gene therapy

There have been rare instances like with scientist James Wilson where researchers were involved in what I would call major misconduct but somehow managed to bounce back. In a sense, they were given second chances in part by regulators but also by other scientists or supporters. However, after extraordinary misconduct, especially contributing to the death

2nd chances after big misconduct? He Jiankui, James Wilson, others Read More »

Reviews of P shot & O shot stabs at sexual enhancement

Something called a P shot has sparked interest from some men interested in high-risk attempts at enhancement. The goal of today’s review post is to fact-check P shots. They’re sold for supposed penis enhancement or to address erectile dysfunction (ED). I’ll also fact-check so-called O shot stabs at vaginal rejuvenation or enhancement. These are both

Reviews of P shot & O shot stabs at sexual enhancement Read More »

Weekly reads: Marc Tessier-Lavigne probe, Neuralink on the brain, Ras unchained

Marc Tessier-Lavigne

We’ll start with a story related to possible research misconduct, Stanford’s President Marc Tessier-Lavigne, and Science Magazine.  In some ways the news on Science itself could be the bigger long-term story. Marc Tessier-Lavigne pub investigation, Science oops moment Here’s some of the coverage: Stanford investigates potential misconduct in president’s research, Science. Multiple publications of Marc Tessier-Lavigne

Weekly reads: Marc Tessier-Lavigne probe, Neuralink on the brain, Ras unchained Read More »

Weekly reads: NurOwn, key gene screen, MS, Croce mess

Nurown BrainStorm

I get a lot of questions about stem cells for ALS and more recently people have been specifically interested in NurOwn from BrainStorm Cell Therapeutics. Recently, the FDA denied BrainStorm’s request for a BLA for NurOwn. The company felt its Phase III trial was encouraging. It sounds like they will move forward with a follow-up

Weekly reads: NurOwn, key gene screen, MS, Croce mess Read More »

What is Mastodon & why so far it’s a clunky alternative to Twitter

Mastodon

Lately it seems like something called Mastodon is on the minds of many a Twitter user. There is a wave of people tweeting “let’s dump Twitter and go to Mastodon now that Musk has taken over!” However, so far I don’t see Mastodon as a solid alternative to the admittedly annoyingly musky Twitter. I do

What is Mastodon & why so far it’s a clunky alternative to Twitter Read More »

Weekly reads: KRAS G12C, eLife journal controversy, bird iPSCs

KRAS mutations, KRAS G12C

If you’ve never heard of the KRAS G12C mutation, it’s a particularly frightening mutation present in numerous cancers. Like the MYC oncogene, many people view mutations in RAS as undruggable, but new efforts show some glimmers of hope. The drug Sotorasib has been approved by the FDA to target the KRAS G12C mutation. Here’s a

Weekly reads: KRAS G12C, eLife journal controversy, bird iPSCs Read More »